New-onset atrial fibrillation in critically ill patients

Canadian Respiratory Journal

Volumn 22, Issue 3, 2015, Pages 179-182

  Sibley, Stephanie ^a   Muscedere, John ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Atrial fibrillation; Critically ill; Intensive care

Indexed keywords

ANTICOAGULATION; BRAIN ISCHEMIA; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CRITICALLY ILL PATIENT; DISEASE SEVERITY; HUMAN; INCIDENCE; INTENSIVE CARE; INTENSIVE CARE UNIT; MORBIDITY; MORTALITY; NEW-ONSET ATRIAL FIBRILLATION; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; SURGICAL PATIENT; ATRIAL FIBRILLATION;

ATRIAL FIBRILLATION; CRITICAL CARE; HUMANS;

EID: 84930590416     PISSN: 11982241     EISSN: 19167245     Source Type: Journal    
DOI: 10.1155/2015/394961     Document Type: Review

References (55)

1. Salman S, Bajwa A, Gajic O, et al. Paroxysmal atrial fibrillation in critically ill patients with sepsis. J Intensive Care Med 2008;23:178-83.
2. Kanji S, Williamson DR, Yaghchi BM, et al. Epidemiology and management of atrial fibrillation in medical and noncardiac surgical adult intensive care unit patients. J Crit Care 2012;27:e321-8.
3. Seguin P, Launey Y. Atrial fibrillation is not just an artefact in the ICU. Crit Care 2010;14:182.
4. Chen AY, Sokol SS, Kress JP, et al. New-onset atrial fibrillation is an independent predictor of mortality in medical intensive care unit patients. Ann Pharmacother 2015;49:523-7.
5. Rivero-Ayerza M, Scholte Op Reimer W, Lenzen M, et al. New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: Results of the Euroheart Failure Survey. Eur Heart J 2008;29:1618-24.
6. Reinelt P, Karth GD, Geppert A, et al. Incidence and type of cardiac arrhythmias in critically ill patients: A single center experience in a medical-cardiological ICU. Intensive Care Med 2001;27:1466-73.
7. Passman RS, Gingold DS, Amar D, et al. Prediction rule for atrial fibrillation after major noncardiac thoracic surgery. Ann Thorac Surg 2005;79:1698-703.
8. Asfar P, Meziani F, Hamel JF, et al. High versus low blood-pressure target in patients with septic shock. N Engl J Med 2014;370:1583-93.
9. Meierhenrich R, Steinhilber E, Eggermann C, et al. Incidence and prognostic impact of new-onset atrial fibrillation in patients with septic shock: A prospective observational study. Crit Care 2010;14:R108.
10. Seguin P, Laviolle B, Maurice A, et al. Atrial fibrillation in trauma patients requiring intensive care. Intensive Care Med 2006;32:398-404.
11. Xia VW, Worapot A, Huang S, et al. Postoperative atrial fibrillation in liver transplantation. Am J Transplant 2015;15:687-694.
12. Walkey AJ, Wiener RS, Ghobrial JM, et al. Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. JAMA 2011;306:2248-54.
13. Walkey AJ, Hammill BG, Curtis LH, et al. Long-term outcomes following development of new-onset atrial fibrillation during sepsis. Chest 2014;146:1187-95.
14. Neumar RW, Otto CW, Link MS, et al. Part 8: Adult advanced cardiovascular life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2010;122(18 Suppl 3):S729-67.
15. Joglar JA, Kowal RC. Electrical cardioversion of atrial fibrillation. Cardiol Clin 2004;22:101-11.
16. Mayr A, Ritsch N, Knotzer H, et al. Effectiveness of direct-current cardioversion for treatment of supraventricular tachyarrhythmias, in particular atrial fibrillation, in surgical intensive care patients. Crit Care Med 2003;31:401-5.
17. Oral H, Souza JJ, Michaud GF, et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 1999;340:1849-54.
18. Caldeira D, David C, Sampaio C. Rate versus rhythm control in atrial fibrillation and clinical outcomes: Updated systematic review and meta-analysis of randomized controlled trials. Arch Cardiovasc Dis 2012;105:226-38.
19. Gillis AM, Verma A, Talajic M, et al. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: Rate and rhythm management. Can J Cardiol 2011;27:47-59.
20. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64:e1-76.
21. Abrams J, Allen J, Allin D, et al. Efficacy and safety of esmolol vs propranolol in the treatment of supraventricular tachyarrhythmias: A multicenter double-blind clinical trial. Am Heart J 1985;110:913-22.
22. Platia EV, Michelson EL, Porterfield JK, et al. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol 1989;63:925-9.
23. Demircan C, Cikriklar HI, Engindeniz Z, et al. Comparison of the effectiveness of intravenous diltiazem and metoprolol in the management of rapid ventricular rate in atrial fibrillation. Emerg Med J 2005;22:411-4.
24. Delle Karth G, Geppert A, Neunteufl T, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med 2001;29:1149-53.
25. Siu CW, Lau CP, Lee WL, et al. Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation. Crit Care Med 2009;37:2174-9.
26. Koh KK, Kwon KS, Park HB, et al. Efficacy and safety of digoxin alone and in combination with low-dose diltiazem or betaxolol to control ventricular rate in chronic atrial fibrillation. Am J Cardiol 1995;75:88-90.
27. Kochiadakis GE, Kanoupakis EM, Kalebubas MD, et al. Sotalol vs metoprolol for ventricular rate control in patients with chronic atrial fibrillation who have undergone digitalization: A single-blinded crossover study. Europace 2001;3:73-9.
28. Hofmann R, Steinwender C, Kammler J, et al. Effects of a high dose intravenous bolus amiodarone in patients with atrial fibrillation and a rapid ventricular rate. Int J Cardiol 2006;110:27-32.
29. Clemo HF, Wood MA, Gilligan DM, et al. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol 1998;81:594-8.
30. Ashrafian H, Davey P. Is amiodarone an underrecognized cause of acute respiratory failure in the ICU? Chest 2001;120:275-82.
31. Balser JR, Martinez EA, Winters BD, et al. Beta-adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias. Anesthesiology 1998;89:1052-9.
32. Moran JL, Gallagher J, Peake SL, et al. Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmias: A prospective, randomized study. Crit Care Med 1995;23:1816-24.
33. Ho KM, Sheridan DJ, Paterson T. Use of intravenous magnesium to treat acute onset atrial fibrillation: A meta-analysis. Heart 2007;93:1433-40.
34. Sleeswijk ME, Tulleken JE, Van Noord T, et al. Efficacy of magnesiumamiodarone step-up scheme in critically ill patients with new-onset atrial fibrillation: Aprospective observational study. J Intensive Care Med 2008;23:61-6.
35. Ganga HV, Noyes A, White CM, et al. Magnesium adjunctive therapy in atrial arrhythmias. Pacing Clin Electrophysiol 2013;36:1308-18.
36. Kanji S, Stewart R, Fergusson DA, et al. Treatment of new-onset atrial fibrillation in noncardiac intensive care unit patients: A systematic review of randomized controlled trials. Crit Care Med 2008;36:1620-4.
37. Barranco F, Sanchez M, Rodriguez J, et al. Efficacy of flecainide in patients with supraventricular arrhythmias and respiratory insufficiency. Intensive Care Med 1994;20:42-4.
38. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8.
39. Varriale P, Sedighi A. Acute management of atrial fibrillation and atrial flutter in the critical care unit: Should it be ibutilide? Clin Cardiol 2000;23:265-68.
40. Camm AJ, Capucci A, Hohnloser SH, et al. A randomized activecontrolled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011;57:313-21.
41. Freemantle N, Lafuente-Lafuente C, Mitchell S, et al. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace 2011;13:329-45.
42. Heldal M, Atar D. Pharmacological conversion of recent-onset atrial fibrillation: A systematic review. Scand Cardiovasc J 2013;(Suppl)47:2-10.
43. Walkey AJ, Greiner MA, Heckbert SR, et al. Atrial fibrillation among medicare beneficiaries hospitalized with sepsis: Incidence and risk factors. Am Heart J 2013;165:949-55.
44. Darwish OS, Strube S, Nguyen HM, et al. Challenges of anticoagulation for atrial fibrillation in patients with severe sepsis. Ann Pharmacother 2013;47:1266-71.
45. Lip GY, Frison L, Halperin JL, et al. Identifying patients at high risk for stroke despite anticoagulation: A comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010;4:2731-8.
46. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest 2010;137:263-72.
47. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010;138:1093-100.
48. Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001;344:1411-20.
49. Weigner MJ, Thomas LR, Patel U, et al. Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: Short-term safety and impact on maintenance of sinus rhythm at 1 year. Am J Med 2001;110:694-702.
50. Airaksinen KE, Gronberg T, Nuotio I, et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: The Fincv (Finnish Cardioversion) study. J Am Coll Cardiol 2013;62:1187-92.
51. Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: A retrospective analysis. Am J Cardiol 1998;82:1545-7;A1548.
52. Knotzer H, Mayr A, Ulmer H, et al. Tachyarrhythmias in a surgical intensive care unit: A case-controlled epidemiologic study. Intensive Care Med 2000;26:908-14.
53. Kuipers S, Klein Klouwenberg P, Cremer OL. Incidence, risk factors and outcomes of new-onset atrial fibrillation in patients with sepsis: A systematic review. Crit Care 2014;18:688.
54. Arora S, Lang I, Nayyar V, et al. Atrial fibrillation in a tertiary care multidisciplinary intensive care unit-incidence and risk factors. Anaesth Intensive Care 2007;35:707-13.
55. Seguin P, Signouret T, Laviolle B, et al. Incidence and risk factors of atrial fibrillation in a surgical intensive care unit. Crit Care Med 2004;32:722-6.